Health Condition 1: - Health Condition 2: - Health Condition 3: B998- Other infectious disease
Conditions
Interventions
Intervention1: Aibendazole And Praziquantel Combination Therapy: Albendazole(15mg/kg/day)for 28 days plus praziquantel(50mg/kg/day) for 14 days plus standard treatment
Control Intervention1: Albendazo
Sponsors
Virender Gehlawat
Eligibility
Inclusion criteria
Inclusion criteria: Children aged 1- 14 years with multiple neurocysticercosis will be enrolled satisfying following criteria 1.Conclusive demonstration of scolex within a cystic lesion on neuroimaging studies. 2.cystic lesion without a discernible scolex 3.Enhancing lesions. 4.Multilobulated cystic lesions in the subarachnoid space
Exclusion criteria
Exclusion criteria: 1.Children with single lesion and more than five lesions at diagnosis. 2.Children with extraparenchymal lesions including intraocular and intraventricular NCC. 3. Children with encephalopathy and signs of raised intracranial pressure. 4.Chidren who have recieved antiparasitic drugs in preceding 3 months. 5.Children with intellectual disability or global developmental delay, coexisting neurodegenerative/ neurometabolic or any other structural pathology. 6.Children with recognised progressive neurological illness. 7. Children with renal, pulmonary, cardiac or hepatic dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of children with complete resolution of all viable and non calcified cysts at six monthsTimepoint: six months | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effectsTimepoint: 6 months;Calcification of cystTimepoint: 6 months;Seizure recurrenceTimepoint: 6 months | — |
Countries
India
Contacts
Public ContactVijay Rani
Pt. B.D Sharma Post Graduate Institute Of Medical Sciences ,Rohtak
Outcome results
None listed